Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers-Reference-Cited by-同舟云学术

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

Published:2017-11-06 Issue:12 Volume:49 Page:1693-1704
ISSN:1061-4036
Container-title:Nature Genetics
language:en
Short-container-title:Nat Genet

Author:

Blakely Collin M,Watkins Thomas B K,Wu Wei,Gini Beatrice,Chabon Jacob J,McCoach Caroline E,McGranahan Nicholas,Wilson Gareth A,Birkbak Nicolai J,Olivas Victor R,Rotow Julia,Maynard Ashley,Wang Victoria,Gubens Matthew A,Banks Kimberly C^ORCID,Lanman Richard B^ORCID,Caulin Aleah F,St John John,Cordero Anibal R,Giannikopoulos Petros,Simmons Andrew D,Mack Philip C,Gandara David R,Husain Hatim,Doebele Robert C,Riess Jonathan W,Diehn Maximilian^ORCID,Swanton Charles,Bivona Trever G

Publisher

Springer Science and Business Media LLC

Subject

Genetics

Link

http://www.nature.com/articles/ng.3990.pdf

Reference37 articles.

1. de Bruin, E.C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251–256 (2014).

2. Zhang, J. et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346, 256–259 (2014).

3. Turke, A.B. et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77–88 (2010).

4. Zhang, Z. et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 44, 852–860 (2012).

5. Chabon, J.J. et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat. Commun. 7, 11815 (2016).

Cited by 429 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chitinase 3-like-1 (CHI3L1) in the pathogenesis of epidermal growth factor receptor mutant non-small cell lung cancer;Translational Oncology;2024-11

2. Identifying cooperating cancer driver genes in individual patients through hypergraph random walk;Journal of Biomedical Informatics;2024-09

3. Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status;BMC Pulmonary Medicine;2024-08-24

4. SAFE-MIL: a statistically interpretable framework for screening potential targeted therapy patients based on risk estimation;Frontiers in Genetics;2024-08-15

5. Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial;Signal Transduction and Targeted Therapy;2024-08-13